| dc.contributor.advisor | Londoño Patiño, John Darío | |
| dc.contributor.advisor | Granados, Carlos Eduardo | |
| dc.contributor.author | Cubides Acosta, María Fernanda | |
| dc.date.accessioned | 2012-02-07T19:26:17Z | |
| dc.date.available | 2012-02-07T19:26:17Z | |
| dc.date.issued | 2012-02-07 | |
| dc.identifier.citation | Latin American Rheumatology Associations of the PanAmerican League of
Associations for Rheumatology (PANLAR) Grupo Latinoamericano de Estudio de
Artritis Reumatoide (GLADAR) First Latin American position paper on the
pharmacological treatment of rheumatoid arthritis Rheumatology. 2006;45:7–22 | |
| dc.identifier.citation | Grupo de Expertos de la Asociación Colombiana de Reumatología, Primer Consenso
Colombiano Sobre el tratamiento de la Artritis Reumatoide Temprana, Rev Colomb
Reumatol. 2002; 9 323- 331 | |
| dc.identifier.citation | Mora C, Díaz J, Quintana G. Costos directos de la artritis reumatoide temprana en el
primer año de atención: simulación de tres situaciones clínicas en un hospital
universitario de tercer nivel en Colombia. Biomedica. 2009;29:43-50. | |
| dc.identifier.citation | Cardiel MH. First Latin American position paper on the pharmacological treatment of
rheumatoid arthritis. Rheumatology 2006, 45 Suppl 2:7-22 | |
| dc.identifier.citation | Yelin E, Meenan R, Nevitt M, Epstein W. Work disability in rheumatoid arthritis:
effects of disease, social, and work factors.[Abstract] Ann Intern Med. 1980; 93:551–6. | |
| dc.identifier.citation | Bukhari MA, Wiles NJ, Lunt M, Harrison BJ, Scott Symmons DP, et al. Influence of
disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at
five years: results from a large observational inception study. Arthritis Rheum.
2003;48:46–53 | |
| dc.identifier.citation | Anaya JM , Correa PA, Mantilla RD , Jimenez F , Kuffner T , McNicholl JM
Rheumatoid arthritis in African Colombians from Quibdo. Semin Arthritis Rheum.
2001 31:191-8 | |
| dc.identifier.citation | Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The
American Rheumatism Association 1987 revised criteria for the classification of
rheumatoid arthritis. Arthritis Rheum. 1988 31:315-24 | |
| dc.identifier.citation | Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The
American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in
Rheumatoid Arthritis Clinical Trials. Arthritis Rheum. 1993; 36:729-40. | |
| dc.identifier.citation | Cardiel MH, Abello-Banfi M, Ruiz-Mercado R, Alarcon-Segovia D. How to measure
health status in rheumatoid arthritis in non-English speaking patients: validation of a
Spanish version of the Health Assessment Questionnaire Disability Index (Spanish
HAQ-DI). Clin Exp Rheumatol. 1993; 11:117-21. | |
| dc.identifier.citation | Prevoo ML, Vant Hof MA, Kuper HH, et al. Modified disease activity scores that
include twenty eight joint counts . Development and validation in a prospective
longitudinal study of patients with rheumatoid arthritis . Arthritis Rheum 1995; 38: 44
-8 | |
| dc.identifier.citation | Gandek B, Ware JE, Aaronson NK, Apolone G, Bjorner JB, Brazier JE, et al. Crossvalidation of item selection and scoring for the SF-12 Health Survey in nine countries:
results from the IQOLA Project. International Quality of Life Assessment. J Clin
Epidemiol. 1998; 51:1171-8 | |
| dc.identifier.citation | O'DeU JR, Haire CE, Erikson N, Dtymalski W, Palmer W, Eckhoff PJ, etal. Treatment
of rheumatoid arthritis with methotrexate alone, sulphasalazine and
hydroxychloroquine, or a combination of all three medications. N EngI J
Med.1996;334:1287-91. | |
| dc.identifier.citation | Fox Rl, Herrmann ML, Frangou CG, Wahl GM, Morris RE, Strand V, et al.
Mechanism of action for leflunomide in rheumatoid arthritis. Clin
Immunol.1999;93:198-208. | |
| dc.identifier.citation | Strand V, Cohen S, Schif FM, Weaver A, Fleischmann R, Cannon G, et al.Treatment of
active rheumatoid arthritis with leflunomide compared with placebo and methotrexate.
Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med. 1999;
159:2542-50 | |
| dc.identifier.citation | Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, et al. Efficacy and
safety of leflunomide compared with placebo and sulphasalazine in naive rheumatoid
arthritis: a double-blind, randomised, multicenter trial. European Leflunomide Study
Group. Lancet. 1999;353 :259-66. | |
| dc.identifier.citation | Weinblatt ME, Kremer JM, Coblyn JS, Maier AL,Helfgott SM, Morrell M, et al.
Pharmacokinetics, safety and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum.
1999;42:1322-8. | |
| dc.identifier.citation | S-S Lee, Y-W Park, JJ Park, YM Kang, EJ Nam, SI Kim, JH Lee, W-H Yoo,
Combination treatment with leflunomide and methotrexate for patients with active
rheumatoid arthritis Scand J Rheumatol 2009;38:11–14 | |
| dc.identifier.citation | Vibeke Strand; Stanley Cohen,Michael Schiff, Arthur Weaver, Roy
Fleischmann;Grant Cannon, Treatment of Active Rheumatoid Arthritis With
Leflunomide Compared With Placebo and Methotrexate, Arch Intern Med. 1999.159 :
2543-50 | |
| dc.identifier.citation | Kremer JM, Genovese MC, Cannon GW, et al. Concomitant leflunomide therapy in
patients with active rheumatoid arthritis despite stable doses of methotrexate. A
randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2002;137:726–33. | |
| dc.identifier.citation | Furst D, Luggen M, Thompson A, Coleman J. Adding leflunomide to patients with
active rheumatoid arthritis while receiving methotrexate improves physical function
and health-related quality of life [abstract]. Arthritis Rheum 2000;43 Suppl:344 | |
| dc.identifier.citation | Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G, et al. Combination
therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J
Med 1995;333:137–41. | |
| dc.identifier.citation | Cherwinski HM, Cohn RG, Cheung P, Webster DJ, Xu YZ, Caulfield JP, et al. The
immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting
pyrimidine biosynthesis. J Pharmacol Exp Ther 1995;275:1043–9. | |
| dc.identifier.citation | Cronstein BN. Molecular therapeutics: methotrexate and its mechanism of action.
Arthritis Rheum 1996;39:1951–60 | |
| dc.identifier.citation | Van Riel P. Leflunomide improves the clinical response in patients with active
rheumatoid arthritis treated with methotrexate. Clin Exp Rheumatol 2003;21:695–6. | |
| dc.identifier.citation | Antony T, Jose VM, Paul BJ, Thomas T. Efficacy and safety of leflunomide alone and
in combination with methotrexate in the treatment of refractory rheumatoid arthritis.
Indian J Med Sci. 2006;60:318-26. | |
| dc.identifier.citation | Willkens RF, Urowitz MB, Stablein DM, McKendry RJR Jr, Berger RG, Box JH, et al.
Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum
1992;35:849–56 | |
| dc.identifier.citation | Williams HJ, Ward JR, Reading JC, Brooks RH, Clegg DO, Skosey JL, et al.
Comparison of auranofin, methotrexate, and the combination of both in the treatment
of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 1992;35:259–69. | |
| dc.identifier.citation | Osiri M, Shea B, Robinson V, Suarez-Almazor M, Strand V, Tugwell P, et al
Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 2003;30: 1182–90. | |
| dc.identifier.uri | http://hdl.handle.net/10818/1231 | |
| dc.description.abstract | La combinación metotrexade -leflunoamida es eficaz en el tratamiento de la artritis reumatoide (AR) aunque su seguridad ha sido cuestionada. Objetivos: Evaluar la eficacia y seguridad de la combinación metotrexate – leflunoamida en el tratamiento de pacientes con AR que han fallado a la terapia convencional. Métodos: Estudio 2 semanas que incluyo 88 pacientes, se evaluó la actividad de la enfermedad mediante: Respuesta ACR, DAS 28, HAQ para la capacidad funcional y SF12 para la calidad de vida. La seguridad se evaluó mediante el registro de eventos adversos y resultados de laboratorio. Resultados: 72(82%) pacientes completaron el estudio. Hubo mejoría significativa de la enfermedad. Se presentaron 30 eventos adversos. Conclusiones: la combinación de metotrexate-leuflonoamida es efectiva pero se requiere control estricto. | es_CO |
| dc.language.iso | spa | es_CO |
| dc.subject | Artritis reumatoide -- Investigaciones -- Colombia | es_CO |
| dc.subject | Artritis reumatoide -- Enfermedades -- Colombia | |
| dc.subject | Artritis -- Tratamiento -- Colombia | |
| dc.title | Eficacia y seguridad de la combinación metotrexate leflunomida en una cohorte colombiana de pacientes con artritis reumatoide: estudio multicéntrico | es_CO |
